Huma acquires Alcedis to expand clinical trial platform
Huma acquires Alcedis to expand clinical trial platform unknown
Digital health tech company Huma acquired clinical trial data specialist Alcedis, expanding the British company's capabilities in the digital clinical trial space.
Huma will create an advanced clinical trials division utilizing German-based Alcedis' platform that will offer digital health solutions spanning various stages of the development process, from early stage development to phase 4 decentralized clinical trials.
"We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma's award-winning technology-platform. Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organization and academic partners for their research projects," Hanno Härtlein, managing director at Alcedis, said in a statement.
THE LARGER TREND
In 2020, Huma underwent a rebranding and acquired AI and wearable tech companies, Biobeats and Tarilian Laser Technologies, which it said reinforced its mission to play a pioneering role in discovering digital biomarkers.
A year later, France-based information technology company Atos and Huma announced a five-year strategic global partnership aiming to shift healthcare and clinicals trials from the hospital to home. The partnership would also support pharmaceutical and research industries to run global decentralized clinical trials.
Last year, Huma acquired London-based patient engagement firm iPLATO. The companies were slated to continue operating independently, but combine their expertise to allow for more predictive and personalized patient care.
The company also announced a partnership with AstraZeneca to launch Software as a Medical Device (SaMD) companion apps pertaining to multiple therapeutic areas aimed at accelerating adoption of decentralized clinical trials.
At the time, CNBC reported the pharma giant also took a $33 million stake in the British health tech firm, while Huma acquired AstraZeneca's disease management platform for asthma and heart failure patients dubbed AMAZE, which the companies would work together to scale.